Polen Capital Management LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Polen Capital Management LLC trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 960,537 shares of the company’s stock after selling 166,610 shares during the quarter. IDEXX Laboratories accounts for approximately 2.8% of Polen Capital Management LLC’s portfolio, making the stock its 15th largest holding. Polen Capital Management LLC owned about 1.20% of IDEXX Laboratories worth $649,832,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 11.9% during the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares during the last quarter. Nordea Investment Management AB boosted its holdings in IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the last quarter. NEOS Investment Management LLC boosted its holdings in IDEXX Laboratories by 82.7% during the 3rd quarter. NEOS Investment Management LLC now owns 30,051 shares of the company’s stock worth $19,199,000 after acquiring an additional 13,599 shares during the last quarter. Procyon Advisors LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth $1,966,000. Finally, Diversified Trust Co. boosted its holdings in IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock worth $2,841,000 after acquiring an additional 2,901 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on IDXX shares. UBS Group cut their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Finally, Stifel Nicolaus cut their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX opened at $557.91 on Friday. The company’s 50-day moving average is $563.14 and its 200 day moving average is $628.16. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $44.01 billion, a P/E ratio of 41.08, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.